SG Americas Securities
CRNX

SG Americas Securities’s Crinetics Pharmaceuticals CRNX Stock Holding History

SG Americas Securities’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Buy
25,210
+15,639
+163% +$581K ﹤0.01% 1913
2026
Q1 		$348K Sell
9,571
-12,218
-56% -$546K ﹤0.01% 2379
2025
Q4 		$1.01M Sell
21,789
-10,482
-32% -$467K ﹤0.01% 2006
2025
Q3 		$1.34M Buy
32,271
+11,989
+59% +$383K ﹤0.01% 1208
2025
Q2 		$583K Sell
20,282
-501,984
-96% -$15.5M ﹤0.01% 1564
2025
Q1 		$17.5M Sell
522,266
-20,180
-4% -$754K 0.06% 223
2024
Q4 		$27.7M Buy
542,446
+529,483
+4,085% +$29.6M 0.11% 96
2024
Q3 		$662K Sell
12,963
-66,088
-84% -$3.41M ﹤0.01% 1443
2024
Q2 		$3.54M Buy
79,051
+73,084
+1,225% +$3.38M 0.02% 701
2024
Q1 		$279K Buy
+5,967
New +$233K ﹤0.01% 1737
2023
Q2 		– Sell
-26,166
Closed -$420K – 2454
2023
Q1 		$420K Buy
26,166
+16,399
+168% +$303K ﹤0.01% 1853
2022
Q4 		$179K Sell
9,767
-5,559
-36% -$98K ﹤0.01% 2279
2022
Q3 		$301K Sell
15,326
-10,066
-40% -$205K ﹤0.01% 1989
2022
Q2 		$474K Buy
+25,392
New +$507K 0.01% 2004
2022
Q1 		– Sell
-6,366
Closed -$181K – 3042
2021
Q4 		$181K Sell
6,366
-12,901
-67% -$318K ﹤0.01% 2725
2021
Q3 		$406K Buy
+19,267
New +$403K ﹤0.01% 2687
2020
Q3 		– Sell
-14,802
Closed -$259K – 2838
2020
Q2 		$259K Buy
+14,802
New +$252K ﹤0.01% 2629

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's CRNX Position: Q2 2026 in Review

SG Americas Securities increased its Crinetics Pharmaceuticals (CRNX) stake by 163% in Q2 2026, buying an estimated $581K and bringing the position to 25,210 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

SG Americas Securities first reported a position in CRNX in Q2 2020 and has held it in 17 quarters since. The position peaked at $27.7M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • SG Americas Securities held 25,210 shares of Crinetics Pharmaceuticals worth $943K as of Q2 2026.
  • SG Americas Securities bought 15,639 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $581K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1913 holding.
  • SG Americas Securities first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • SG Americas Securities's Crinetics Pharmaceuticals position peaked at $27.7M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.